Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 300

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function

Open access
Saxena, Varun, Koraishy, Farrukh M., Sise, Meghan E., Lim, Joseph K., Schmidt, Monica, Chung, Raymond T., Liapakis, Annmarie, Nelson, David R., Fried, Michael W., Terrault, Norah A., HCV‐TARGET · 2016 · Liver International

Abstract

Background & Aims: Renal clearance is the major elimination pathway for sofosbuvir (SOF). We assessed the safety and efficacy of SOF‐containing regimens in patients with varying baseline estimated glomerular filtration rate (eGFR). Methods: HCV‐TARGET database is a multicentre, longitudinal ‘real‐world’ treatment cohort. Results: A total of 1789 patients [genotypes 1 (72%), 2 (17%) 3 (9%), 4–6 (2%)] had baseline eGFR determination: 73 with eGFR≤45 (18 with eGFR≤30, 5 on dialysis) were compared to 1716 with eGFR>45 ml/min/1.73 m 2. Patients with baseline eGFR≤45 vs. >45 differed in being female (55% vs. 36%), age ≥65 years (24% vs. 16%), Black race (22% vs. 12%), having cirrhosis with decompensation (73% vs. 24%) and being post‐transplant (49% vs. 10%), all P < 0.05. All patients with eGFR≤45 were treated with SOF 400 mg/day (including those on haemodialysis) and had median starting ribavirin (RBV) dose of 800 mg (IQR: 400–1200). Sustained virologic response (SVR) frequencies were similar across eGFR groups, ranging from 82–83%. Patients with eGFR ≤45 more frequently experienced anaemia, worsening renal function and serious AE s (all P < 0.05), and these associations persisted when limiting analysis to RBV‐free regimens. Patients with baseline eGFR≤30 and eGFR 31–45 had similar frequencies of efficacy and safety outcomes. Conclusions: Sustained viral clearance was achieved in 83% of patients with renal impairment (eGFR ≤45 ml/min/1.73 m 2) treated with SOF‐containing regimens. However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV. Patient with renal impairment require close monitoring and should be treated by providers extensively experienced with SOF‐containing regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13102

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 300

Metadata

Authors
Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A., & HCV‐TARGET
Venue
Liver International
Publisher
Wiley
Published
2016-03-24
Volume
36
Issue
6
Pages
807-816
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2284028703
Cited by
300
References
8
FWCI
42.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. https://app.cochat.ai/papers/10.1111/liv.13102
The paper
Saxena, V., Koraishy, F. M., Sise, M. E., Lim, J. K., Schmidt, M., Chung, R. T., Liapakis, A., Nelson, D. R., Fried, M. W., Terrault, N. A., & HCV‐TARGET. (2016). Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function. Liver International. https://doi.org/10.1111/liv.13102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.